Autore: Ved Srivastava

Ved Srivastava is Vice President of Chemistry and co-founder at Phoundry Pharmaceuticals, and prior to that he was head of Peptide Chemistry at Glaxo Smith Kline and Vice President of research and production at New England Peptide. He spent several years with Amylin Pharmaceuticals where he focused on discovery and development of novel peptide hormones for diabetes, obesity and neuropsychiatric therapies. He has significantly contributed in the development of Byetta TM, Symlin TM and Bydeureon TM for the treatment of diabetes. He also directed the research chemistry team of Psylin Neurosciences, Inc., a biotech company formed as a joint venture between Amylin Pharmaceuticals, Inc. and Pshycho Genics, Inc.  Ved has over 25 years of experience with expertise in drug discovery in the area metabolic diseases and inflammation with major emphasis in peptide medicinal chemistry and peptide delivery. He earned a Ph.D.in organic chemistry from the University of Lucknow, India and had subsequent postdoctoral appointments at the University of Georgia and the University of Colorado Medical School. Ved is energetically involved in the governance of the American Peptide Society.